Introduction: Life expectancy improvement for people living with Human Immunodeficiency Virus (HIV) is coming up against the problems associated with aging and chronic diseases. Frailty is a concern affecting a growin...Introduction: Life expectancy improvement for people living with Human Immunodeficiency Virus (HIV) is coming up against the problems associated with aging and chronic diseases. Frailty is a concern affecting a growing number of patients, particularly the elderly in this population. Our study aimed to determine the prevalence of frailty and its predictors on people living with HIV aged 50 years and older followed at the Outpatient Treatment Clinic (CTA) in Dakar. Methodology: We conducted a cross-sectional study of descriptive and analytic purposes ranging from November 2022 to August 2023, in CTA, Dakar (Senegal). We included people living with HIV aged 50 years and older under antiretroviral therapy for at least 6 months (≥6 months). Frailty was considered according to Fried criteria with a score ≥3. To identify the predictors of frailty, we performed a multivariate logistic regression analysis using STATA software version 18. Results: We included 199 patients. The median age at the moment of the study was 58 years old [50 - 91] with a sex ratio (M/F) of 0.58. The most representative age group was that of [50 - 59] years (59.3%). HIV-1 profile was most common in 89.45%. The median duration under antiretroviral therapy was 180 months [6 - 284] and 94% of patients received a Tenofovir Disoproxil Fumarate (TDF)-containing regimen with 43% of them for at least 10 years. Viral load was undetectable (≤40 copies/ml) in 98% of cases. WHO Stage III was more common at inclusion and 55.78% had nadir TCD4+ Lymphocyte counts Conclusion: Our study confirms the high prevalence of frailty among older people living with HIV. Its prevention should consider the management of comorbidities and the implementation of non-pharmacological interventions such as nutrition.展开更多
Introduction: Coronavirus disease is a pandemic discovered in December 2019. It is a polymorphic, systemic zoonosis caused by a virus with predominant respiratory tropism. This work aimed to evaluate the epidemiologic...Introduction: Coronavirus disease is a pandemic discovered in December 2019. It is a polymorphic, systemic zoonosis caused by a virus with predominant respiratory tropism. This work aimed to evaluate the epidemiological, clinical, paraclinical, therapeutic, and evolutionary profile of patients with COVID-19 at Touba Ndamatou Public Hospital Hospital Establishment. Materials and Methods: This was a descriptive, retrospective, cross-sectional study of 114 cases hospitalized for COVID-19 at Touba Ndamatou Public Hospital Health Establishment, during the period from May 1, 2020, to September 30, 2021. Data were collected from patient medical records, entered using Epi Info Version 7 software, and analyzed using SSPS version 21.0 software. Results: The mean age of patients was 65 ± 14.5 years, with extremes of 25 and 92 years. The predominant age group was [46 - 65 years] with 39%. Males predominated with 65% (n = 74). The peak occurred in August 2021 with 57.8% of cases (n = 66). 68.15% of patients had at least one comorbidity, with hypertension and diabetes the most frequent comorbidities at 35.9% and 15.7% respectively. Dyspnea was the most frequent reason for consultation (70%), while the most common physical signs were pulmonary condensation syndrome (94%), respiratory distress (77%), and hypoxia (65%). Severe forms accounted for 32%. The most common CT images were ground-glass areas, predominantly in the basithoracic region. Azithromycin was used in all patients, oxygen therapy was used in 93%, and corticosteroids were used in 90%, although the average number of drugs taken per patient was eight (8). The average hospital stay was 4.54 days. The case fatality rate was 18.51% (n = 21). Advanced age (60 and over) and hypoxia were the main risk factors for mortality. Conclusion: The COVID-19 pandemic has been declared a global health emergency by the WHO. It has caused many deaths worldwide. Vaccination, the subject of much controversy in our context, would be the only means of preventing critical forms of the disease, especially among people at risk.展开更多
文摘Introduction: Life expectancy improvement for people living with Human Immunodeficiency Virus (HIV) is coming up against the problems associated with aging and chronic diseases. Frailty is a concern affecting a growing number of patients, particularly the elderly in this population. Our study aimed to determine the prevalence of frailty and its predictors on people living with HIV aged 50 years and older followed at the Outpatient Treatment Clinic (CTA) in Dakar. Methodology: We conducted a cross-sectional study of descriptive and analytic purposes ranging from November 2022 to August 2023, in CTA, Dakar (Senegal). We included people living with HIV aged 50 years and older under antiretroviral therapy for at least 6 months (≥6 months). Frailty was considered according to Fried criteria with a score ≥3. To identify the predictors of frailty, we performed a multivariate logistic regression analysis using STATA software version 18. Results: We included 199 patients. The median age at the moment of the study was 58 years old [50 - 91] with a sex ratio (M/F) of 0.58. The most representative age group was that of [50 - 59] years (59.3%). HIV-1 profile was most common in 89.45%. The median duration under antiretroviral therapy was 180 months [6 - 284] and 94% of patients received a Tenofovir Disoproxil Fumarate (TDF)-containing regimen with 43% of them for at least 10 years. Viral load was undetectable (≤40 copies/ml) in 98% of cases. WHO Stage III was more common at inclusion and 55.78% had nadir TCD4+ Lymphocyte counts Conclusion: Our study confirms the high prevalence of frailty among older people living with HIV. Its prevention should consider the management of comorbidities and the implementation of non-pharmacological interventions such as nutrition.
文摘Introduction: Coronavirus disease is a pandemic discovered in December 2019. It is a polymorphic, systemic zoonosis caused by a virus with predominant respiratory tropism. This work aimed to evaluate the epidemiological, clinical, paraclinical, therapeutic, and evolutionary profile of patients with COVID-19 at Touba Ndamatou Public Hospital Hospital Establishment. Materials and Methods: This was a descriptive, retrospective, cross-sectional study of 114 cases hospitalized for COVID-19 at Touba Ndamatou Public Hospital Health Establishment, during the period from May 1, 2020, to September 30, 2021. Data were collected from patient medical records, entered using Epi Info Version 7 software, and analyzed using SSPS version 21.0 software. Results: The mean age of patients was 65 ± 14.5 years, with extremes of 25 and 92 years. The predominant age group was [46 - 65 years] with 39%. Males predominated with 65% (n = 74). The peak occurred in August 2021 with 57.8% of cases (n = 66). 68.15% of patients had at least one comorbidity, with hypertension and diabetes the most frequent comorbidities at 35.9% and 15.7% respectively. Dyspnea was the most frequent reason for consultation (70%), while the most common physical signs were pulmonary condensation syndrome (94%), respiratory distress (77%), and hypoxia (65%). Severe forms accounted for 32%. The most common CT images were ground-glass areas, predominantly in the basithoracic region. Azithromycin was used in all patients, oxygen therapy was used in 93%, and corticosteroids were used in 90%, although the average number of drugs taken per patient was eight (8). The average hospital stay was 4.54 days. The case fatality rate was 18.51% (n = 21). Advanced age (60 and over) and hypoxia were the main risk factors for mortality. Conclusion: The COVID-19 pandemic has been declared a global health emergency by the WHO. It has caused many deaths worldwide. Vaccination, the subject of much controversy in our context, would be the only means of preventing critical forms of the disease, especially among people at risk.
